Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01313)
Name	Paclitaxel
Synonyms	Click to Show/Hide the Synonyms of This API paclitaxel; TAXOL; 33069-62-4; Taxol A; Abraxane; Yewtaxan; Paxene; Genaxol; Paxceed; Plaxicel; Onxol; ABI-007; Ebetaxel; Genetaxyl; Capxol; Intaxel; LipoPac; OncoGel; Paclitaxel (Taxol); Genexol; Pacliex; TaxAlbin; Zisu; NSC-125973; EmPAC; Onxal; ABI 007; BMS 181339-01; UNII-P88XT4IS4D; MBT 0206; NSC125973; Mitotax; NSC 125973; HSDB 6839; DHP 107; DRG-0190; MFCD00869953; NK 105; QW 8184; P88XT4IS4D; BMS-181339-01; CHEMBL428647; 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; CHEBI:45863; nab-paclitaxel; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R,betaS),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; NCGC00164367-01; Cyclopax; Padexol; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate; Anzatax; Cynviloq; Nanoxel; Sindaxel; Xorane; Cypher select; Coroflex Please; Taxus stent; Taxus Express; Taxus Liberte; 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (NAB)-Paclitaxel; SMR000857385; EndoTAG 1; EndoTAG-1; LEP-ETU; SR-01000075350; Abraxane I.V. Suspension; Infinnium; Nanotaxel; Paclical; Pacligel; Paxoral; Paclitaxel/; CCRIS 8143; taxol derivatives; Genexol-PM; Paclitaxel,(S); Paclitaxel [USAN:USP:INN:BAN]; Abraxane (TN); (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; [diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate; Nanoparticle albumin bound paclitaxel; CAS-33069-62-4; IG 001; BMS-181339; Paclitaxel-SSMM-VIP; Liposome-entrapped paclitaxel easy-to-use; P-SSMM-VIP; Prestwick3_000155; DSSTox_CID_3413; TAXOL (TN); SCHEMBL3976; DSSTox_RID_77016; Nova-12005; Paclitaxel, Taxus brevifolia; BIDD:PXR0046; DSSTox_GSID_23413; BSPBio_000290; KBioGR_002509; KBioSS_002517; Paclitaxel (JAN/USP/INN); MLS002154218; MLS002695976; OAS-PAC-100; BPBio1_000320; GTPL2770; MEGxp0_001940; Taxol (TN) (Bristol Meyers); DTXSID9023413; ACon1_002231; KBio2_002509; KBio2_005077; KBio2_007645; KBio3_002987; ANX-513; DHP-107; DHP-208; DTS-301; SDP-013; cMAP_000068; HMS2090D07; HMS2095O12; HMS2231A16; HMS3712O12; Abraxane (albumin-bound suspension); ACT02709; HY-B0015; MPI-5018; Tox21_112107; ABP000252; BDBM50001839; NSC745099; ZINC96006020; AKOS007930675; AKOS015969673; AKOS025312303; ACN-032459; CCG-220155; CS-1145; DB01229; GS-6554; NSC-745099; QW-8184; NCGC00164367-02; NCGC00164367-03; NCGC00164367-04; NCGC00164367-05; NCGC00164367-10; Paclitaxel, From Taxus brevifolia, 95%; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; NCI60_000601; Paclitaxel, from Taxus yannanensis, powder; AB0069184; AB00513812; N1361; D00491; M-8858; M02242; N88686; 10337-EP2269989A1; 10337-EP2270018A1; 10337-EP2272827A1; 10337-EP2272832A1; 10337-EP2277507A1; 10337-EP2277865A1; 10337-EP2277876A1; 10337-EP2280012A2; 10337-EP2280014A2; 10337-EP2281815A1; 10337-EP2281820A2; 10337-EP2286795A1; 10337-EP2287168A2; 10337-EP2289876A1; 10337-EP2289892A1; 10337-EP2292233A2; 10337-EP2292234A1; 10337-EP2292614A1; 10337-EP2292615A1; 10337-EP2295412A1; 10337-EP2295413A1; 10337-EP2295416A2; 10337-EP2298748A2; 10337-EP2298754A1; 10337-EP2298772A1; 10337-EP2298780A1; 10337-EP2301533A1; 10337-EP2301536A1; 10337-EP2301538A1; 10337-EP2301928A1; 10337-EP2301933A1; 10337-EP2301940A1; 10337-EP2302382A2; 10337-EP2302383A2; 10337-EP2305243A1; 10337-EP2305250A1; 10337-EP2305640A2; 10337-EP2305642A2; 10337-EP2305671A1; 10337-EP2305679A1; 10337-EP2305689A1; 10337-EP2305808A1; 10337-EP2308833A2; 10337-EP2308839A1; 10337-EP2308861A1; 10337-EP2311455A1; 10337-EP2311808A1; 10337-EP2311827A1; 10337-EP2311829A1; 10337-EP2314295A1; 10337-EP2314574A1; 10337-EP2316452A1; 10337-EP2316832A1; 10337-EP2316833A1; AB00513812-02; AB00513812-03; 069P624; Paclitaxel, Antibiotic for Culture Media Use Only; Q423762; 7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.; Q-201533; SR-01000075350-1; SR-01000075350-3; SR-01000075350-6; SR-01000075350-7; SR-01000075350-9; BRD-K62008436-001-03-1; BRD-K62008436-001-05-6; BRD-K62008436-001-22-1; Paclitaxel, from semisynthetic (from Taxus sp.), >=97%; Paclitaxel, European Pharmacopoeia (EP) Reference Standard; Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder; Paclitaxel, United States Pharmacopeia (USP) Reference Standard; 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material; 7,11-METHANO-5H-CYCLODECA[3,4]BENZ[1,2-B]OXETE BENZENEPROPANOIC ACID DERIV.; Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R,betaS),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12; (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 1203669-79-7; 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; 5?,20-Epoxy-1,7?-dihydroxy-9-oxotax-11-ene-2?,4,10?,13?-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]; Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R,.beta.S),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-; Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2a-alpha,4-beta,4a-beta,6-beta,9-alpha(alpha-R,beta-S),11-alpha,12-alpha,12a-alpha, 12b-alpha))-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR,betaS),11alpha,12alpha,12aalpha,12balpha))-; Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard; Paclitaxel semi-synthetic for system suitability, European Pharmacopoeia (EP) Reference Standard; Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha- hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (8CI); Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (8CI); Tax-11-en-9-one,20-epoxy-1,2.alpha.,4,7.beta., 10.beta.,13.alpha.- hexahydroxy-, 4,10-diacetate 2- benzoate,13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Clinical Status	Approved
PubChem CID	36314
Formula	C47H51NO14
Canonical SMILES	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
InChI	1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
InChIKey	RCINICONZNJXQF-MZXODVADSA-N
	Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure	<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=36314"></iframe>
Structure	3D MOL is unavailable		2D MOL
Physicochemical Properties	Molecular Weight	853.9	Topological Polar Surface Area	221
	XlogP	2.5	Complexity	1790
	Heavy Atom Count	62	Rotatable Bond Count	14
	Hydrogen Bond Donor Count	4	Hydrogen Bond Acceptor Count	14

Full List of Drug Formulations (DFMs) Containing This API
Paclitaxel 6mg/ml injectable			Click to Show/Hide the Full List of Formulation(s): 3 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Citric Acid; Dehydrated Alcohol; Purified Polyoxyl 35 Castor Oil
Dosage Form	Injectable
Company	Msn Laboratories Private Limited
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Kyselina citronova	DIG Info	Perilipin-1 (IC50 = 3708 nM)	[1]
	Polyoxyl 35 castor oil	DIG Info	Cholesterol 25-hydroxylase (EC50 = 1.1 uM)	[2]
Drug Formulation 2	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Purified Cremophor El (Polyoxyethylated Castor Oil); Citric Acid Anhydrous; Dehydrated Alcohol
Dosage Form	Injectable
Company	Actavis Pharma
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Kyselina citronova	DIG Info	Perilipin-1 (IC50 = 3708 nM)	[1]
	Polyoxyl 35 castor oil	DIG Info	Cholesterol 25-hydroxylase (EC50 = 1.1 uM)	[2]
Drug Formulation 3	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Purified Polyoxl 35 Castor Oil; Dehydrated Alcohol
Dosage Form	Injectable
Company	Wg Critical Care
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Polyoxyl 35 castor oil	DIG Info	Cholesterol 25-hydroxylase (EC50 = 1.1 uM)	[2]

References
1	PubChem BioAssay data set.
2	Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.